Custom Search
Trazodone News
Labopharm reports results for second quarter fiscal 2007
Once-Daily Trazodone
Anti-depressants reduce bone density
People who use selective serotonin re-uptake inhibitors to treat depression have a decreased bone density, a new research shows.
Labopharm starts phase III antidepressant study
Labopharm has begun enrolling patients in its phase III trial for its once-daily formulation of the antidepressant trazodone.
Biloba Drug Ginkgo Interaction
The following paragraphs summarize the work of Biloba Drug Ginkgo Interaction experts who are completely familiar with all the aspects of Biloba Drug Ginkgo Interaction. Heed their advice to avoid any Biloba Drug Ginkgo...
A meta-analysis of clinical trials comparing the serotonin (5HT)-2 receptor antagonists trazodone and nefazodone with selective serotonin reuptake inhibitors for the treatment of major depressive disorder
Objective: To compare response rates among patients with major depressive disorder (MDD) treated with either a serotonin-2 (5HT2-) receptor antagonist or a selective serotonin reuptake inhibitor (SSRI).